why choose us

First received: February 05, 2024

Clinical Trial: A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Advanced Stage Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of JNJ-79032421, a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors

Brief Summary: The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).

Read more